FrancophonIA/ELRC3.0 huggingface dataset:
English: Duloxetine Lilly demonstrated statistically significant superiority over placebo as measured by improvement in the Hamilton Anxiety Scale (HAM-A) total score and by the Sheehan Disability Scale (SDS) global functional impairment score.
Maltese: Duloxetine Lilly wera superjorità statistikament sinifikanti fuq plaċebo kemm meta kkalkulat skont it titjib fil-punteġġ totali tal-Hamilton Anxiety Scale (HAM-A) u kemm skont il-punteġġ ta' indeboliment funzjonali globali tas-Sheehan Disability Scale (SDS).
English: Interstitial lung disease10
Maltese: Mard talinterstizju talpulmun10
English: Treatment with duloxetine showed a statistically significantly greater improvement in GAD symptoms, as measured by PARS severity score for GAD (mean difference between duloxetine and placebo of 2.7 points [95% CI 1.3-4.0]), after 10 weeks of treatment.
Maltese: GAD (differenza medja bejn duloxetine u plaċebo ta' 2.7 punti [95% CI 1.3-4.0]), wara 10 ġimgħat ta' kura.
English: Duloxetine is extensively metabolised by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6), followed by conjugation.
Maltese: Duloxetine huwa metaboliżżat b'mod estensiv minn enżimi ossidattivi (CYP1A2 u dik polymorfika CYP2D6) u mbagħad ikkonjugat.
English: Studies in juvenile rats reveal transient effects on neurobehaviour, as well as significantly decreased body weight and food consumption; hepatic enzyme induction; and hepatocellular vacuolation at 45 mg/kg/day.
Maltese: Studji f'firien mhux adulti wrew effetti temporanji fuq l-imġiba newrotika, kif ukoll tnaqqis sinifikanti fil-piż tal-ġisem u l-konsum tal-ikel; stimulazzjoni tal-enzimi epatiċi; u vakwolazzjoni epatoċellulari b'45 mg/kg/jum.
English: Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).
Maltese: Is-sintomi tas-sindromu ta' serotonin jistgħu jinkludu tibdil fl-istat mentali (eż. aġitazzjoni, alluċinazzjonijiet, koma), instabilità sutonomis (eż. takikardija, pressjoni tad-demm li mhijiex stabbli, ipertermija), aberrazzjonijiet newromuskulari (eż. iperriflessi, problemi ta' koordinazzjoni) u/jew sintomi gastrointestinali (eż. dardir, rimettar, dijarea).
English: Extra-pyramidal symptoms6
Maltese: Irrekwitezza psikomotorja6 Sintomi ekstrapiramidali6
English: EU/1/14/972/004 (28 hard gastro-resistant capsules) EU/1/14/972/005 (56 hard gastro-resistant capsules) EU/1/14/972/006 (84 hard gastro-resistant capsules) EU/1/14/972/007 (98 hard gastro-resistant capsules)
Maltese: (28 kapsula gastro-reżistenti iebsa) EU/1/14/972/005 (56 kapsula gastro-reżistenti iebsa) EU/1/14/972/006 (84 kapsula gastro-reżistenti iebsa) EU/1/14/972/007 (98 kapsula gastro-reżistenti iebsa)
English: A total of 509 paediatric patients aged 7 to 17 years with major depressive disorder and 241 paediatric patients aged 7 to 17 years with generalised anxiety disorder were treated with duloxetine in clinical trials.
Maltese: F'provi kliniċi, total ta' 509 pazjenti pedjatriċi b'etajiet minn 7 sa 17-il sena b'disturb depressiv maġġuri u 241 pazjent pedjatriku b'etajiet minn 7 sa 17-il sena b'disturb ta' ansjetà ġeneralizzata ġew ikkurati b'duloxetine.
English: As a general recommendation, caution should be exercised when treating the elderly (see sections 4.2 and 4.4).
Maltese: Bħala rakkomandazzjoni ġenerali, il-kura ta' l anzjani għandha tiġi segwita b'attenzjoni (ara sezzjonijiet 4.2 u 4.4).
English: Dista S.A.. Tel: + 34 91 623 17 32
Maltese: Tel: + 34 91 623 17 32
English: During the 52-week placebocontrolled double blind treatment phase 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p<0.001).
Maltese: 14.4% tal-pazjenti kkurati b'duloxetine u 33.1% tal-pazjenti kkurati bil-plaċebo reġgħu ħassew issintomi depressivi tagħhom (p< 0.001).
English: Edible white ink contains: Titanium dioxide (E171) Propylene glycol Shellac
Maltese: L-inkjostru abjad li jittiekel fih: Titanium dioxide (E171) Propylene glycol Shellac
English: Diabetic Peripheral Neuropathic Pain: As with other medicinal products with similar pharmacological action (antidepressants), isolated cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation.
Maltese: Bħal bi prodotti mediċinali oħra li għandhom azzjoni farmakoloġika simili (anti-depressivi), ġew irrappurtati każi iżolati ta' formazzjoni ta' ideat suwiċidali u mġiba suwiċidali waqt terapija ta' duloxetine jew kmieni wara sospensjoni tal-kura.
English: Ear and labyrinth disorders Tinnitus1
Maltese: Disturbi fil-widnejn u fis-sistema labirintika Tinnitus1
English: • inflammation of the blood vessels in the skin (cutaneous vasculitis)
Maltese: • Infjammazzjoni tal-arterji u tal-vini fil-ġilda (vaskulite kutanea)
English: Duloxetine Lilly 30 mg Duloxetine Lilly 30 mg is available in packs of 7, 28 and 98 hard gastro-resistant capsules.
Maltese: Duloxetine Lilly 30 mg Duloxetine Lilly 30 mg issibu f'pakketti ta' 7, 28 u 98 kapsula gastro-reżistenti iebsa.
English: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
Maltese: Pazjenti bi problemi ereditarji rari ta' intolleranza għal fructose, assorbiment ħażin ta' glucose-galactose jew insuffiċjenza ta' sucroseisomaltase m'għandhomx jieħdu din il-mediċina.
English: EU/1/14/972/008 (100 hard gastro-resistant capsules) (5 packs of 20) EU/1/14/972/009 (500 hard gastro-resistant capsules) (25 packs of 20)
Maltese: EU/1/14/972/008 (100 kapsula gastro-reżistenti iebsa) (5 pakketti ta' 20)
English: No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients.
Maltese: Ma ġiet osservata l-ebda differenza klinikament sinifikanti meta ġie kkalkulat il-QT, il-PR, il-QRS, jew il-QTcB bejn pazjenti fuq kura ta' duloxetine u pazjenti fuq il-plaċebo.
English: Capsule shell:
Maltese: KARTUN GĦALL-KAPSULI
English: Two randomized, double-blind, parallel clinical trials were performed in 800 paediatric patients aged 7 to 17 years with major depressive disorder (see section 4.2).
Maltese: Saru żewġ provi kliniċi magħmula b'mod arbitrarju, paralleli u double-blind f'800 pazjent pedjatriku b'etajiet bejn 7 sa 17-il sena b'disturb depressiv maġġuri (ara sezzjoni 4.2).
English: Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6.
Maltese: Duloxetine huwa inibitur moderat ta' CYP2D6.
English: Duloxetine binds to both albumin and alpha-l acid glycoprotein.
Maltese: Duloxetine jintrabat kemm ma' l-albumina kif ukoll ma' alpha-1 acid glycoprotein.
English: Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.
Maltese: Ibbażati fuq studji in vitro, il-prodotti metaboliċi ta' duloxetine li jiċċirkolaw huma kkunsidrati farmakoloġikament inattivi.
English: Consequently, caution is advised when Duloxetine Lilly is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Maltese: Konsegwentement, huwa rrakkomandat li Duloxetine Lilly jingħata b'attenzjoni meta jittieħed flimkien ma' prodotti mediċinali jew sustanzi li jaħdmu b'mod ċentrali fosthom alkoħol u prodotti mediċinali sedattivi (eż. benzodiazepines, morfinomimetiċi, anti-psikotiċi,
English: Concomitant use of Duloxetine Lilly with nonselective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated (see section 4.5).
Maltese: L-użu fl-istess ħin ta' Duloxetine Lilly ma' inibituri ta' monoamine oxidase (MAOIs) irriversibbli u mhux selettivi huwa kontraindikat (ara sezzjoni 4.5).
English: Duloxetine Lilly 30 mg Opaque white body, imprinted with ‘30 mg' and an opaque blue cap, imprinted with ‘9543'.
Maltese: Duloxetine Lilly 30 mg Il-parti prinċipali abjad opak, stampat b' ‘30 mg' u għatu blu opak, stampat b' ‘9543'.
English: Lactation did not influence duloxetine pharmacokinetics.
Maltese: It-treddigħ m'affettwax il-farmakokinetika ta' duloxetine.
English: Duloxetine Lilly 60 mg to 120 mg once daily demonstrated statistically significant superiority compared to placebo (p<0.001) on the prevention of relapse, as measured by time to relapse.
Maltese: Duloxetine Lilly 60 mg sa 120 mg kuljum wera superjorità statistikament sinifikanti meta mqabbel ma' plaċebo (p<0.001) fil-prevenzjoni ta' rikaduta, ikkalkulata skont iż-żmien għar-rikaduta.
English: Elimination The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours).
Maltese: Il-half life ta' l-eliminazzjoni ta' duloxetine tvarja minn 8 sa 17-il siegħa (medja ta' 12-il siegħa).
English: Oral contraceptives and other steroidal agents: Results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A.
Maltese: Riżultati ta' studji in vitro juru li duloxetine ma jistimulax l-attività katalitika ta' CYP3A.
English: Effects of other medicinal products on duloxetine Antacids and H2 antagonists: Co-administration of duloxetine with aluminium- and magnesiumcontaining antacids or duloxetine with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Maltese: Effetti ta'prodotti mediċinali oħra fuq duloxetine Mediċini kontra l-aċtu fl-istonku u antagonisti ta' H2: It-teħid ta' duloxetine flimkien ma' mediċini kontra l-aċtu fl-istonku li fihom aluminium u magnesium jew ma' famotidine ma kellhiex effett sinifikanti fuq ir-rata jew il-miżura ta' assorbiment ta' duloxetine wara li ngħatat doża orali ta' 40 mg.
English: The efficacy of Duloxetine Lilly 30-120 mg (flexible dosing) once a day in elderly patients (>65 years) with generalised anxiety disorder was evaluated in a study that demonstrated statistically significant improvement in the HAM-A total score for duloxetine treated patients compared to placebo treated patients.
Maltese: L-effikaċja ta' Duloxetine Lilly 30-120 mg (dożaġġ flessibbli) darba kuljum f'pazjenti anzjani (>65 sena) b'disturb ta' ansjetà ġeneralizzata ġiet evalwata fi studju li wera titjib statistikament sinifikanti fil-punteġġ totali tal-HAM-A f'pazjenti kkurati b'duloxetine meta mqabbel ma' pazjenti kkurati bil-plaċebo.
English: Mydriasis
Maltese: Midrijasi
English: Sodium lauryl sulfate Titanium dioxide (E171) Indigo carmine (E132) Edible green ink
Maltese: Sodium lauryl sulfate Titanium dioxide (E171)
English: Muscle spasm
Maltese: Uġigħ muskoluskeletali
English: There was no statistically significant difference in discontinuation due to adverse events between duloxetine and placebo groups during the 10 week acute treatment phase.
Maltese: Ma kien hemm ebda differenza statistikament sinifikanti ta' twaqqif mill-kura minħabba avvenimenti avversi bejn il-grupp ta' duloxetine u l-grupp tal-plaċebo matul il-fażi akuta ta' kura ta' 10 ġimgħat.
English: Cases of liver injury, including severe elevations of liver enzymes (>10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8).
Maltese: (>10 darbiet il-limitu ta' fuq tan-normal), epatite u suffejra (ara sezzjoni 4.8).
English: Therefore, caution should be exercised when treating the elderly with the maximum dosage (see sections 4.2 and 5.2).
Maltese: Għaldaqstant, il-kura ta' anzjani b'doża massima għandha tiġi segwita b'attenzjoni (ara sezzjonijiet 4.2 u 5.2).
English: Hyponatraemia may be due to a syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Maltese: sekrezzjoni mhux f'loka tal-ormon anti-dijuretiku (SIADH).
English: Treatment of major depressive disorder.
Maltese: Kura ta' disturb depressiv maġġuri.
English: Duloxetine Lilly 60 mg Opaque green body, imprinted with ‘60 mg' and an opaque blue cap, imprinted with ‘9542'.
Maltese: Duloxetine Lilly 60 mg Il-parti prinċipali aħdar opak, stampat b' ‘60 mg' u għatu blu opak, stampat b' ‘9542'.
English: Somnolence
Maltese: Insomnja
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Mediċini: http://www.ema.europa.eu
English: Talk to your doctor before you take Duloxetine Lilly if you: - are taking other medicines to treat depression (see ‘Other medicines and Duloxetine Lilly') - are taking St. John's Wort, a herbal treatment (Hypericum perforatum) - have kidney disease - have had seizures (fits) - have had mania - suffer from bipolar disorder - have eye problems, such as certain kinds of glaucoma (increased pressure in the eye) - have a history of bleeding disorders (tendency to develop bruises) - are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly) - are currently being treated with another medicine which may cause liver damage - are taking other medicines containing duloxetine (see ‘Other medicines and Duloxetine Lilly')
Maltese: qiegħed/qiegħda tieħu St.John's Wort, kura bbażata fuq il-ħxejjex (Hypericum perforatum) għandek mard tal-kliewi għandek passat ta' aċċessjonijiet għandek passat ta' manija tbati minn mard bipolari għandek problemi f'għajnejk bħal xi tip ta' glawkoma (pressjoni għolja fl-għajn) għandek passat ta' emorraġija (tendenza li tiżviluppa tbenġil) qiegħed/qiegħda f'riskju li jitbaxxielek il-livell ta' sodium (per eżempju jekk qiegħed/qiegħda tieħu d-dijuretiċi, speċjalment jekk inti anzjan/anzjana) qiegħed/qiegħda tirċievi fl-istess waqt kura b'mediċina oħra li tista' tikkawżalek ħsara fil fwied qiegħed/qiegħda tieħu mediċini oħra li fihom duloxetine (ara ‘Medicini oħra u Duloxetine
English: 7 hard gastro-resistant capsules 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
Maltese: 28 kapsula gastro-reżistenti iebsa 98 kapsula gastro-reżistenti iebsa
English: A meta-analysis of placebo-controlled clinical trials of antidepressant medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Maltese: Analiżi ta' numru ta' studji kliniċi kkontrollati bil-plaċebo ta' prodotti mediċinali antidepressivi li ntużaw f'disturbi psikjatriċi wrew riskju ogħla ta' mġiba suwiċidali bl-antidepressivi meta mqabbla ma' plaċebo f'pazjenti iżgħar minn 25 sena.
English: There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs), including duloxetine.
Maltese: Ġew irrappurtati fsada mhux normali, bħal ekimosi, purpura u emorraġija gastro-intestinali b'inibituri selettivi ta'ġbir mill-ġdid ta' serotonin (SSRIs) u inibituri ta' ġbir mill-ġdid ta' serotonin/noradrenaline
English: The potential risk for humans is unknown.
Maltese: Mhux magħruf ir-riskju potenzjali għall-umani.
English: A randomised, double-blind, placebo-controlled study was performed in 272 patients aged 7-17 years with generalised anxiety disorder.
Maltese: Sar studju magħmul b'mod arbitrarju, double-blind u kkontrollat bil-plaċebo f'272 pazjent b'etajiet bejn 7-17-il sena b'disturb ta' ansjetà ġeneralizzata.
English: Hepatitis3
Maltese: ANNESS III
English: The plasma concentration of duloxetine displays large inter-individual variability (see section 5.2).
Maltese: Il-konċentrazzjoni fil plażma ta' duloxetine turi varjabbilità kbira bejn individwu u ieħor (ara sezzjoni 5.2).
English: The therapeutic benefit should be reassessed regularly (at least every three months) (see section 5.1).
Maltese: Il-benefiċċju terapewtiku għandu jerġa' jiġi valutat regolarment (mill-anqas kull tliet xhur) (ara sezzjoni 5.1).
English: Hyper-sensitivity disorder
Maltese: Indeboliment fil-vista
English: Duloxetine Lilly should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
Maltese: Duloxetine Lilly m'għandux jiġi użat flimkien ma' fluvoxamine, ciprofloxacin jew enoxacin (jiġifieri inibituri qawwija ta' CYP1A2) billi dan iwassal għal konċentrazzjonijiet elevati ta' duloxetine fil plażma (ara sezzjoni 4.5).
English: Inducers of CYP1A2: Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers.
Maltese: Sustanzi li jistimulaw CYP1A2: Analiżi farmakokinetiċi ta' popolazzjoni juru li min ipejjep għandu kważi 50% anqas konċentrazzjonijiet fil-plażma ta' duloxetine meta mqabbla ma' min ma jpejjipx.
English: Gastrointestinal disorders Nausea
Maltese: Disturbi gastro-intestinali
English: The no-adverse effect level was determined to be 20 mg/kg/day.
Maltese: 20 mg/kg/jum.
English: The incidence of relapse during the 6-months double-blind follow-up period was 14% for Duloxetine Lilly and 42% for placebo.
Maltese: L-inċidenza ta' rikaduta waqt il-perijodu miżjud ta' 6 xhur li kien double-blind kien ta' 14 %
English: Pharmacokinetic differences have been identified between younger and elderly females (≥65 years) (AUC increases by about 25% and half-life is about 25% longer in the elderly), although the magnitude of these changes is not sufficient to justify adjustments to the dose.
Maltese: Differenzi farmakokinetiċi kienu identifikati bejn nisa żgħar u kbar (≥ 65 sena) (l-AUC jiżdied b'madwar 25% u l-half life hi madwar 25% itwal fl-anzjani), għalkemm id-daqs ta' dawn il-bidliet mhux biżżejjed biex jiġġustifikaw tibdil fid-doża.
English: Malaise
Maltese: Disgewżja
English: 6.5 Nature and contents of container
Maltese: 6.1 Lista ta' eċċipjenti
English: Medicinal products metabolised by CYP1A2: The pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily).
Maltese: CYP1A2, ma ġietx affettwata b'mod sinifikanti meta ngħata flimkien ma' duloxetine (60 mg darbtejn kuljum).
English: When stopping treatment with Duloxetine Lilly the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8).
Maltese: Meta l-kura b'Duloxetine Lilly tkun ser titwaqqaf id doża għandha tiġi mnaqqsa gradwalment fuq perijodu ta' mill-anqas ġimgħa sa ġimagħtejn sabiex jitnaqqas ir-riskju ta' reazzjonijiet ta' rtirar (ara sezzjonijiet 4.4 u 4.8).
English: Duloxetine Lilly demonstrated statistical superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale (HAM-D) total score (including both the emotional and somatic symptoms of depression).
Maltese: Duloxetine Lilly statistikament wera superjorità fuq plaċebo kkalkulat skont it-titjib fil-punteġġ totali tal-Hamilton Depression Rating Scale (HAM-D) bi 17-il kriterju (li jinkludu kemm sintomi ta' depressjoni emozzjonali kif ukoll dawk somatiċi).
English: Suicide-related behaviours (suicide attempts and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger), were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo.
Maltese: Imġiba assoċjata mas-suwiċidju (attentati ta' suwiċidju u ħsibijiet suwiċidali), u ostilità (l-aktar aggressjoni, imġiba konfrontali, u rabja), kienu osservati aktar spiss f'provi kliniċi fuq tfal u adolexxenti kkurati b'anti depressivi meta mqabbla ma' dawk ikkurati bil-plaċebo.
English: Menopausal symptoms Galactorrhoea Hyperprolactinae mia
Maltese: PREKAWZJONIJIET SPEĊJALI GĦAR-RIMI TA' PRODOTTI MEDIĊINALI MHUX
English: Fatigue
Maltese: Stomatite
English: After an oral dose the apparent plasma clearance of duloxetine ranges from 33 to 261 l/hr (mean 101 l/hr).
Maltese: Wara doża orali, it-tneħħija apparenti ta' duloxetine mill-plażma tvarja minn 33 sa 261 l/hr
English: Breast feeding
Maltese: Spażmu muskolari
English: Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day have been evaluated from a safety perspective in clinical trials.
Maltese: Dożi ta' aktar minn 60 mg darba kuljum, sa doża massima ta' 120 mg kuljum, ġew valutati mill-aspett tas-sigurtà f'provi kliniċi.
English: Respiratory, thoracic and mediastinal disorders Yawning
Maltese: Disturbi respiratorji, toraċiċi u medjastinali Titwib
English: The most commonly reported reactions are listed in section 4.8.
Maltese: L-aktar reazzjonijiet komuni li ġew irraportati huma mniżżlin f'sezzjoni 4.8.
English: Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules duloxetine (as hydrochloride)
Maltese: Duloxetine Lilly 30 mg kapsuli gastro-reżistenti ibsin Duloxetine Lilly 60 mg kapsuli gastro-reżistenti ibsin duloxetine (bħala hydrochloride)
English: The general toxicity profile of duloxetine in juvenile rats was similar to that in adult rats.
Maltese: Il-profil tat-tossiċità ġenerali ta' duloxetine fil-firien mhux adulti kien simili għal dak ta' firien adulti.
English: Other medicines and Duloxetine Lilly
Maltese: Mediċini oħra u Duloxetine Lilly
English: • dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.
Maltese: Sturdament, disturbi tas-sensi (fosthom parastizja jew sensazzjonijiet li jixbħu dak ta' xokk elettriku, speċjalment fir-ras), disturbi fl-irqad, (fosthom insomnja u ħolm intens), għeja, ħedla ta' rqad, aġitazzjoni jew ansjetà, dardir u/jew rimettar, rogħda, wġigħ ta' ras, uġigħ fil-muskoli, irritabilità,
English: Psychomotor restlessness6
Maltese: Edima anġjo newrotika6
English: Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Lilly if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Maltese: Inibituri ta' monoamine oxidase (MAOI): M'għandekx tieħu Duloxetine Lilly jekk qiegħed/qiegħda tieħu jew ħadt recentament (f'dawn l-aħħar 14-il ġurnata) xi mediċina oħra kontra d-depressjoni msejħa inibitur ta' monamino oxidase.
English: Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUCo-t 6-fold.
Maltese: CYP1A2, naqqas it-tneħħija tal-plażma apparenti ta' duloxetine b'madwar 77% u żied b'6 darbiet l
English: Contains sucrose See leaflet for further information
Maltese: Kontenut tal-pakkett u informazzjoni oħra
English: Data on the use of Duloxetine Lilly 120 mg in elderly patients with major depressive disorder and generalised anxiety disorder are limited.
Maltese: Anzjani L-informazzjoni dwar l-użu ta' Duloxetine Lilly 120 mg f'pazjenti anzjani b'disturb depressiv maġġuri u b'disturb ta' ansjetà ġeneralizzata hija limitata.
English: Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules
Maltese: Duloxetine Lilly 30 mg kapsuli gastro-reżistenti ibsin Duloxetine Lilly 60 mg kapsuli gastro-reżistenti ibsin